Built for Your Team

The Decision Your Role Demands, Structured Before You Ask

Whether you're defending a commercial position, evaluating an asset, or reviewing cross study evidence, Kognitic structures the oncology intelligence your role runs on, before you have to ask for it.

Commercial Strategy & Competitive Intelligence

Quantify Market Risk Before the Market Prices It In

Your positioning narrative is only as strong as the evidence underneath it. Kognitic Core structures the competitive landscape into a single view: active trials, pipeline threats, market signals, and endpoint performance, all normalized and continuously updated. Your team stops sourcing and reconciling and starts analyzing.

Competitive monitoring is not a separate function. It is the operating rhythm of your commercial strategy. Core maps competitive positioning and monitors market signals across the full landscape, so the intelligence that informs your next move is structured, not scattered across analyst inboxes.

Competitive Landscape LIVE
NSCLC 2L+ IO Combinations
TreatmentPhaseORRmPFSThreat
Pembro + Chemo You
Ph 3
48%
8.8 mo Low
Dato-DXd + Pembro
Ph 3
52%
11.2 mo High
Nivo + Ipi
Ph 3
36%
6.8 mo Low
Atezo + Bev + Chemo
Ph 3
63%
8.3 mo Med
Ivonescimab
Ph 2
50%
—— High

Competitive Risk

Dato-DXd + Pembro Ph 3 interim shows PFS superiority over Pembro + Chemo in PD-L1 high subgroup

ASCO 2026 · Abstract #LBA4881

Catalyst

FDA PDUFA date for supplemental indication in 1L NSCLC with biomarker stratification

Aug 2026 · Regulatory

247

Active Trials

38

Competitors

12

Pipeline Threats

Core

Business Development & New Product Planning

Validate the Asset Before the Room Asks You To

Every deal memo starts with the same question: does the evidence support the thesis? Kognitic structures published clinical data into a normalized benchmark that stress-tests claims across endpoints, biomarker segments, lines of therapy, and treatment settings. Walk into diligence with a comparative view that holds up under scrutiny.

New product planning and portfolio-level decisions run on the same structured evidence. Launch timing, competitive windows, and portfolio overlap are quantified from the same normalized foundation. The strategic view your committee requires arrives before the meeting, not after three weeks of analyst reconciliation.

Core + Outcomes + API
Asset Evaluation DILIGENCE VIEW

Datopotamab Deruxtecan (Dato-DXd)

Daiichi Sankyo / AstraZeneca

TROP2 ADC NSCLC 2L+ Phase 3
78 Fit

Efficacy vs SOC

ORR (Dato-DXd) 52.1%
SOC (Pembro+Chemo) 48.0%

Median PFS

Dato-DXd + Pembro 11.2 mo
SOC comparator 8.8 mo

Endpoint superiority vs SOC in primary analysis

Manageable safety profile — G3+ lower than comparator

OS data immature, interim only

Crowded competitive landscape in TROP2 ADCs

Advance to Committee Review
Core Outcomes API

Medical Affairs & Scientific Strategy

Trust the Signal, Not the Spreadsheet That Produced It

Your leadership review should start with the analysis, not the data collection. Kognitic structures published clinical evidence into normalized, comparable benchmarks across endpoints, populations, and treatment settings. Efficacy data, safety signals, and patient cohort details from conference abstracts, manuscripts, and registry updates, all reconciled into a single evidence view.

The comparison your review committee requires is delivered before they ask for it. Cross-study evidence is normalized across study designs, reporting standards, and populations, so the conversation moves to interpretation, not data quality.

Core + Outcomes
Evidence Review
NSCLC IO Combinations PFS + OS + ORR

Cross-Study Evidence Comparison | Normalized Endpoints

Study Line ORR mPFS G3+ AEs
KEYNOTE-789 SOC
NCT03515837
2L+
48%
8.8 mo 41.8%
TROPION-Lung04
NCT05129502
2L+
52%
11.2 mo 34.2%
CheckMate-9LA
NCT03215706
1L
36%
6.8 mo 47.0%
IMpower150
NCT02366143
1L
63%
8.3 mo 55.7%
HARMONi-2
NCT06341
1L
50%
11.1 mo 29.4%
6,714

Abstracts

2,847

Drugs

38

Indications

All endpoints normalized across study designs and populations

Core Outcomes
API Explorer
ALL SYSTEMS OPERATIONAL
p99: 47ms

Available Endpoints

GET /api/v2/trials/landscape 12ms
GET /api/v2/drugs/pipeline 18ms
GET /api/v2/efficacy/benchmarks 24ms
POST /api/v2/compare/studies 31ms
GET /api/v2/ontology/dimensions 8ms
GET /trials/landscape — Response Schema OpenAPI 3.1
{
  "indication": "NSCLC", "total_active_trials": 247,
  "meta": { "audit_grade": true, "ontology_dimensions": 9 }
}
Completeness
97.2%
Accuracy
99.1%
Normalization
100%
Python SDK REST API Webhook Events Bulk Export
API

Data Science & Engineering

The Oncology Data Layer Your Team Would Build, Already Built

Building an oncology data infrastructure from scratch means years of ontology development, source integration, and normalization logic. Kognitic has already built it. The API delivers structured, normalized clinical trial data through production-grade endpoints with consistent schemas, living taxonomies, and continuous updates. Your team builds on a validated foundation instead of maintaining one.

The same structured evidence that powers Core and Outcomes is available as machine-ready datasets for your RAG models, AI agents, internal analytics, and BI platforms. No extraction pipelines. No reconciliation cycles. The evidence arrives ready for your models.

Kognitic API

See Which Kognitic Products
Fit Your Workflow

Our team will walk you through a live demonstration in your therapeutic area, structured around the decisions your role requires.